Table 2.
Univariate analysis of factors associated with OS of EHC patients.
| Variables | HR (95% CI) | P |
|---|---|---|
| Gender (male vs. female) | 1.041 (0.663–1.636) | 0.861 |
| Age (≥70 vs. <70 years) | 1.096 (0.712–1.687) | 0.678 |
| Location (HCCA vs. DCCA) | 1.286 (0.806–2.054) | 0.291 |
| CA19-9 (≥643 vs. <643 ng/ml) | 2.199 (1.376–3.516) | 0.001 |
| CEA (≥5.3 vs. <5.3 ng/ml) | 1.460 (0.925–2.304) | 0.104 |
| ALT (≥113 vs. <113 U/l) | 1.292 (0.805–2.075) | 0.288 |
| AST (≥102 vs. <102 U/l) | 1.182 (0.679–2.058) | 0.555 |
| ALP (≥489 vs. <489 U/l) | 1.247 (0.797–1.950) | 0.334 |
| GGT (≥158 vs. <158 U/l) | 1.158 (0.595–2.256) | 0.666 |
| TBIL (≥162 vs. <162 μmol/l) | 2.334 (1.332–4.087) | 0.003 |
| ALB (≤35 vs. >35 g/l) | 1.722 (1.097–2.703) | 0.018 |
| CRP (≥13.9 vs. <13.9 mg/l) | 1.280 (0.818–2.001) | 0.280 |
| PLT (≥175 vs. <175 × 109/l) | 1.186 (0.628–2.239) | 0.599 |
| PT-INR (≥1.17 vs. <1.17) | 1.647 (0.949–2.858) | 0.076 |
| ALBI grade (3 vs. 1–2) | 1.724 (1.100–2.700) | 0.017 |
| CP score (≥8 vs. <8) | 1.683 (1.076–2.633) | 0.023 |
HCCA: hilar cholangiocarcinoma; DCCA: distal cholangiocarcinoma; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; TBIL: total bilirubin; CRP: C-reactive protein; PLT: platelet count; ALB albumin; PT-INR: prothrombin time-international normalized ratio; ALBI: albumin-bilirubin.